Ultra-High Frequency - Electrocardiogram (UHF-ECG) for the Diagnosis of Ventricular Electrical Dyssynchrony (VED)

NCT ID: NCT06641362

Last Updated: 2025-09-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

360 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-03-18

Study Completion Date

2026-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to demonstrate the safety and effectiveness of the VDI UHF-ECG System in the diagnosis of ventricular dyssynchrony when compared to the 12-lead ECG in patients with bradycardia and heart failure indicated for pacemaker implantation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bradycardia Heart Failure Ventricular Dysfunction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment Group

Participant controlled with standard ECG measurement and VDI UHF-ECG measurement both taken sequentially.

Ultra High Frequency Electrocardiogram (UHF-ECG)

Intervention Type DEVICE

Electrocardiograms used on participants scheduled to undergo pacemaker implantation for bradycardia and/or heart failure.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ultra High Frequency Electrocardiogram (UHF-ECG)

Electrocardiograms used on participants scheduled to undergo pacemaker implantation for bradycardia and/or heart failure.

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Standard 12 lead Electrocardiogram (ECG)

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adults with bradycardia scheduled for pacemaker implant or heart failure patients indicated for cardiac resynchronization therapy (CRT) with one of the following:

* Bradycardia with ventricular synchrony and QRS duration \< 110 ms in men or \< 100 ms in women or;
* Bradycardia with left bundle branch block and QRS duration \> 140 ms in men or \> 130 ms in women or;
* Bradycardia with right bundle branch block and QRS duration \> 130 ms in men or \> 120 ms in women or;
* Heart failure with left bundle branch block and QRS duration \> 140 ms in men or \>130 ms in women.
* Understands the nature of the study and is willing to comply with all study requirements.
* Provides written informed consent.
* A negative pregnancy test prior to the procedure for participants of child-bearing potential.

Exclusion Criteria

* Complete AV block (3rd-degree AV block) without a stable escape rhythm or other circumstances where there is no measurable QRS.
* Subjects with a previous or current pacemaker or defibrillator implant.
* Anatomical or other conditions that may make a 12-lead ECG difficult to obtain, such as an allergy to components of the ECG pads, burns, open wounds, etc.
* Currently enrolled in another investigational device or drug trial that has not completed the active treatment phase and/or would conflict with this study.
* Other co-morbid condition(s) that could limit the participant's ability to participate in the study or to comply with study requirements or impact the scientific integrity of the study.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

VDI Technologies

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Peak Heart and Vascular

Avondale, Arizona, United States

Site Status NOT_YET_RECRUITING

Banner Medical Center

Mesa, Arizona, United States

Site Status RECRUITING

University of Chicago

Chicago, Illinois, United States

Site Status RECRUITING

Mayo Clinic

Rochester, Minnesota, United States

Site Status NOT_YET_RECRUITING

Ohio State University

Columbus, Ohio, United States

Site Status RECRUITING

Baylor College of Medicine

Houston, Texas, United States

Site Status RECRUITING

University of Virginia

Charlottesville, Virginia, United States

Site Status RECRUITING

St. Anne's University Hospital

Brno, , Czechia

Site Status NOT_YET_RECRUITING

Catherina Ziekenhuis

Eindhoven, , Netherlands

Site Status NOT_YET_RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States Czechia Netherlands

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Randy LaBounty

Role: CONTACT

9529136050

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Kelly Geeter

Role: primary

602-730-3988

Dalise Dai

Role: primary

Kie Ng

Role: primary

773-702-1015

Adrianne Miller

Role: primary

Stephen Harold

Role: primary

Cathy Roy

Role: primary

Andrej Nagy, MD

Role: primary

References

Explore related publications, articles, or registry entries linked to this study.

Plesinger F, Jurak P, Halamek J, Nejedly P, Leinveber P, Viscor I, Vondra V, McNitt S, Polonsky B, Moss AJ, Zareba W, Couderc JP. Ventricular Electrical Delay Measured From Body Surface ECGs Is Associated With Cardiac Resynchronization Therapy Response in Left Bundle Branch Block Patients From the MADIT-CRT Trial (Multicenter Automatic Defibrillator Implantation-Cardiac Resynchronization Therapy). Circ Arrhythm Electrophysiol. 2018 May;11(5):e005719. doi: 10.1161/CIRCEP.117.005719. Epub 2018 Apr 26.

Reference Type BACKGROUND
PMID: 29700054 (View on PubMed)

Jurak P, Bear LR, Nguyen UC, Viscor I, Andrla P, Plesinger F, Halamek J, Vondra V, Abell E, Cluitmans MJM, Dubois R, Curila K, Leinveber P, Prinzen FW. 3-Dimensional ventricular electrical activation pattern assessed from a novel high-frequency electrocardiographic imaging technique: principles and clinical importance. Sci Rep. 2021 Jun 1;11(1):11469. doi: 10.1038/s41598-021-90963-4.

Reference Type BACKGROUND
PMID: 34075135 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CLIN001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Physiologic Pacing Registry
NCT03719040 COMPLETED
Optimizing CRT With ECGI
NCT03492788 TERMINATED NA